The current study observed no significant differences in overall developmental outcomes or behavior in exposed versus unexposed children.
In this retrospective study of Taiwanese women using antipsychotic medications there was no observed increase in risk of metabolic complications.
Two studies - one using neuropsychological assessments, another examining performance on standardized testing - show no association between prenatal antipsychotic exposure and neurodevelopmental outcomes.
Despite the increasing use of the newer “atypical” or second-generation antipsychotic agents to treat a spectrum of psychiatric disorders, including schizophrenia, bipolar disorder, major depression, PTSD and other anxiety disorders, we have relatively little data [...]
The newer “atypical” or second-generation antipsychotic agents are now used to treat a spectrum of psychiatric disorders, including schizophrenia, bipolar disorder, major depression, PTSD and other anxiety disorders. The National Pregnancy Registry for Atypical Antipsychotics [...]
The use of the newer “atypical” or second-generation antipsychotic (SGA) agents continues to increase. These medications are used to treat a spectrum of psychiatric disorders, including schizophrenia, bipolar disorder, major depression, PTSD and anxiety disorders. [...]
Women with bipolar disorder are at a higher risk for relapse during pregnancy and that the risk is even higher during the postpartum period. In addition, women with bipolar disorder are more vulnerable to postpartum [...]
Despite the increasing use of the newer “atypical” or second-generation antipsychotic agents to treat a spectrum of psychiatric disorders, including schizophrenia, bipolar disorder, major depression, PTSD and other anxiety disorders, we have relatively little data [...]
Despite the increasing use of the newer “atypical” or second-generation antipsychotic agents to treat a spectrum of psychiatric disorders, including schizophrenia, bipolar disorder, major depression, PTSD and other anxiety disorders, we have relatively little data [...]
Despite the increasing use of the newer “atypical” or second-generation antipsychotic agents to treat a spectrum of psychiatric disorders, including schizophrenia, bipolar disorder, major depression, PTSD and other anxiety disorders, we have relatively little data [...]
